| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $282.5M | — | +20.2% |
| Cost of Revenue | $594.2M | — | +28.2% |
| R&D Expense | $335.7M | — | +33.6% |
| SG&A Expense | $304.2M | — | +43.4% |
| Operating Income | -$989.5M | — | -43.0% |
| Pre-tax Income | -$1.03B | — | -179.7% |
| Income Tax | $177K | — | +113.0% |
| Net Income | -$1.03B | — | -180.8% |
| EPS (Basic) | -$3.46 | — | -1341.7% |
| EPS (Diluted) | -$3.46 | — | -1341.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $700.4M | -29.8% | -62.2% |
| Short-term Investments | $0 | -100.0% | -100.0% |
| Accounts Receivable | $131.2M | -25.9% | +45.3% |
| Inventory | $1.47B | +32.4% | +211.6% |
| Current Assets | $2.76B | -16.5% | -37.7% |
| Total Assets | $7.48B |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.19B | — | -176.6% |
| Capital Expenditures | $253.2M | — | +57.0% |
| Investing Cash Flow | $875.2M | — | +42.5% |
| Financing Cash Flow | $35.3M | — | -43.8% |
| Free Cash Flow | -$1.44B | — | -143.9% |
| -18.8% |
| Current Liabilities | $2.69B | +2.2% | +102.4% |
| Long-term Debt | $2.05B | +0.1% | +2.2% |
| Total Liabilities | $5.45B | +1.1% | +24.6% |
| Stockholders' Equity | -$351.4M | -149.0% | -111.0% |